Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-06-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
自愿批露关于签署抗新冠病毒小分子口服药CDMO技术服务及委托生产协议的公告
Regulatory Filings Classification · 90% confidence The document is a voluntary disclosure announcement by 科兴生物制药股份有限公司 regarding the signing of a CDMO technology service and contract manufacturing agreement for an antiviral drug project (SHEN26). It details the parties involved, contract terms, risks, and impact on the company. The document is an announcement of a business cooperation agreement related to drug development and manufacturing, not a financial report, earnings release, or regulatory filing about financial results. It does not contain financial statements or detailed financial data. It is also not a report publication announcement since it does not mention any report being published or attached. The content fits best under Capital/Financing Update (CAP) as it relates to a significant contract affecting the company's operations and potential future revenue streams, but not a direct financing event. However, since it is about a contract signing and business cooperation agreement, and no direct capital raising or financing is mentioned, the best fit is Regulatory Filings (RNS) as a general regulatory announcement about a material contract and business update that does not fit other categories specifically.
2022-06-05 Chinese
上海荣正投资咨询股份有限公司关于科兴生物制药股份有限公司2022年限制性股票激励计划首次授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the "2022 Restricted Stock Incentive Plan First Grant" of a company. It contains detailed analysis, opinions, and approvals related to a stock incentive plan, including grant dates, quantities, prices, and compliance with regulatory rules. The document is not a general annual or quarterly financial report, nor is it a simple announcement or certification. It is a specialized advisory report related to a capital incentive plan, which aligns with the category of Capital/Financing Update (CAP) as it deals with stock grants and equity incentives. The document length is substantial (over 10,000 characters), indicating it is a full report rather than a brief announcement. Therefore, the most appropriate classification is CAP with high confidence.
2022-05-31 Chinese
关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted shares (stock incentives) to eligible recipients by the company 科兴生物制药股份有限公司. It includes specifics such as the grant date, number of shares, pricing, eligibility, approval procedures, legal and financial advisor opinions, and detailed vesting schedules. The content focuses on the company's equity incentive plan and its implementation, which is a capital/financing activity related to share issuance to employees and management. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not related to board changes, voting results, or legal proceedings. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to the specificity and comprehensive nature of the stock incentive plan disclosure.
2022-05-31 Chinese
监事会关于2022年限制性股票激励计划首次授予激励对象名单的核查意见
Governance Information Classification · 95% confidence The document is a supervisory board's verification opinion on the initial grant list of a 2022 restricted stock incentive plan for a company. It discusses compliance with laws and regulations regarding the eligibility of incentive recipients and confirms the grant date and price. This is a detailed governance-related disclosure about stock incentive plans and compliance, not a financial report, earnings release, or capital update. It is not a report publication announcement or a short notice but a formal opinion document. The content aligns best with governance information related to internal rules and compliance with stock incentive plans.
2022-05-31 Chinese
第一届监事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of a restricted stock incentive plan. It details the meeting date, attendance, and the approval of the stock grant to incentive recipients. It references compliance with relevant laws and regulations and confirms the grant date and price. The document is not a full financial report, earnings release, or management discussion, but rather a formal announcement of a board decision related to stock incentives. It is not a proxy solicitation or voting result announcement, but a board/management information disclosure about a corporate governance action. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length is short and focused on a board resolution, not a full report or announcement of a report publication.
2022-05-31 Chinese
2022年限制性股票激励计划首次授予部分激励对象名单（授予日）
Remuneration Information Classification · 95% confidence The document is a detailed list of recipients and allocation of a restricted stock incentive plan for the company 科兴生物制药股份有限公司. It includes names, positions, nationalities, and the number of restricted shares granted. This type of document relates to management compensation and share-based incentives. It is not a full annual report, earnings release, or financial statement. It is not an announcement of voting results or a proxy statement. It is a disclosure related to remuneration and stock incentives for executives and key personnel. Therefore, the document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation and stock incentive plans for top executives and directors.
2022-05-31 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.